Emergent BioSolutions Initiates Pivotal Clinical Trial Evaluating a Three-Dose BioThrax Regimen for Post-Exposure Prophylaxis

ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a pivotal immunogenicity and safety study to evaluate a three-dose vaccination schedule of BioThrax® (Anthrax Vaccine Adsorbed) for administration to individuals exposed to anthrax. Through this pivotal, licensure-enabling clinical study, the company seeks to obtain a post-exposure prophylaxis (PEP) indication for BioThrax.